Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
Erlotinib with bevacizumab showed promising activity in recurrent nonsquamous (NS) nonsmall cell lung cancer (NSCLC). The INNOVATIONS study was designed to assess in first-line treatment of unselected cisplatin-eligible patients this combination compared to cisplatin, gemcitabine and bevacizumab. St...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 2015
|
| In: |
The European respiratory journal
Year: 2015, Jahrgang: 46, Heft: 1, Pages: 219-229 |
| ISSN: | 1399-3003 |
| DOI: | 10.1183/09031936.00229014 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1183/09031936.00229014 Verlag, kostenfrei, Volltext: http://erj.ersjournals.com/content/early/2015/03/18/09031936.00229014 
|
| Verfasserangaben: | Michael Thomas, Jürgen Fischer, Stefan Andreas, Cornelius Kortsik, Christian Grah, Monika Serke, Michael von Eiff, Christian Witt, Jens Kollmeier, Ernst Müller, Michael Schenk, Michael Schröder, Matthias Villalobos, Niels Reinmuth, Roland Penzel, Philipp Schnabel, Thomas Acker, Alexander Reuss, Martin Wolf |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1556148976 | ||
| 003 | DE-627 | ||
| 005 | 20220813154339.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 170331s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1183/09031936.00229014 |2 doi | |
| 035 | |a (DE-627)1556148976 | ||
| 035 | |a (DE-576)486148971 | ||
| 035 | |a (DE-599)BSZ486148971 | ||
| 035 | |a (OCoLC)1340970658 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 245 | 1 | 0 | |a Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer |c Michael Thomas, Jürgen Fischer, Stefan Andreas, Cornelius Kortsik, Christian Grah, Monika Serke, Michael von Eiff, Christian Witt, Jens Kollmeier, Ernst Müller, Michael Schenk, Michael Schröder, Matthias Villalobos, Niels Reinmuth, Roland Penzel, Philipp Schnabel, Thomas Acker, Alexander Reuss, Martin Wolf |
| 264 | 1 | |c July 2015 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 31.03.2017 | ||
| 520 | |a Erlotinib with bevacizumab showed promising activity in recurrent nonsquamous (NS) nonsmall cell lung cancer (NSCLC). The INNOVATIONS study was designed to assess in first-line treatment of unselected cisplatin-eligible patients this combination compared to cisplatin, gemcitabine and bevacizumab. Stage IIIB/IV patients with NS-NSCLC were randomised on erlotinib (150 mg daily) and bevacizumab (15 mg·kg−1 on day 1, every 3 weeks) (EB) until progression, or cisplatin (80 mg·m−2 on day 1, every 3 weeks) and gemcitabine (1250 mg·m−2 on days 1 and 8, every 3 weeks) up to six cycles and bevacizumab (15 mg·kg−1 on day 1, every 3 weeks) (PGB) until progression. 224 patients were randomised (EB n=111, PGB n=113). The response rate (12% versus 36%; p<0.0001), progression-free survival (median 3.5 versus 6.9 months; hazard ratio (HR) 1.85, 95% CI 1.39-2.45; p<0.0001) and overall survival (median 12.6 versus 17.8 months; HR 1.41, 95% CI 1.01-1.97; p=0.04) clearly favoured PGB. In patients with epidermal growth factor receptor mutations (n=32), response rate, progression-free survival and overall survival were not superior with EB. Platinum-based combination chemotherapy remains the standard of care in first-line treatment of unselected NS-NSCLC. Molecular targeted approaches strongly mandate appropriate testing and patient selection. Platinum-based combination chemotherapy remains the standard of care in first-line treatment of unselected NS-NSCLC http://ow.ly/ITkNj | ||
| 700 | 1 | |a Villalobos Bollen, Matthias Americo |d 1974- |e VerfasserIn |0 (DE-588)1078644306 |0 (DE-627)839010133 |0 (DE-576)451580516 |4 aut | |
| 700 | 1 | |a Reinmuth, Niels |d 1970- |e VerfasserIn |0 (DE-588)122316592 |0 (DE-627)705858936 |0 (DE-576)293216266 |4 aut | |
| 700 | 1 | |a Penzel, Roland |e VerfasserIn |0 (DE-588)102044021X |0 (DE-627)691221316 |0 (DE-576)360421083 |4 aut | |
| 700 | 1 | |a Schnabel, Philipp Albert |d 1953-2021 |e VerfasserIn |0 (DE-588)102254960X |0 (DE-627)717000087 |0 (DE-576)16982750X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The European respiratory journal |d Lausanne : ERS, 1988 |g 46(2015), 1, Seite 219-229 |h Online-Ressource |w (DE-627)306646803 |w (DE-600)1499101-9 |w (DE-576)091142504 |x 1399-3003 |7 nnas |a Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer |
| 773 | 1 | 8 | |g volume:46 |g year:2015 |g number:1 |g pages:219-229 |g extent:11 |a Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1183/09031936.00229014 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://erj.ersjournals.com/content/early/2015/03/18/09031936.00229014 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20170331 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 102254960X |a Schnabel, Philipp Albert |m 102254960X:Schnabel, Philipp Albert |d 910000 |d 912000 |e 910000PS102254960X |e 912000PS102254960X |k 0/910000/ |k 1/910000/912000/ |p 16 | ||
| 998 | |g 102044021X |a Penzel, Roland |m 102044021X:Penzel, Roland |d 910000 |d 912000 |e 910000PP102044021X |e 912000PP102044021X |k 0/910000/ |k 1/910000/912000/ |p 15 | ||
| 998 | |g 122316592 |a Reinmuth, Niels |m 122316592:Reinmuth, Niels |d 50000 |e 50000PR122316592 |k 0/50000/ |p 14 | ||
| 998 | |g 1078644306 |a Villalobos Bollen, Matthias Americo |m 1078644306:Villalobos Bollen, Matthias Americo |d 910000 |d 950000 |d 950900 |e 910000PV1078644306 |e 950000PV1078644306 |e 950900PV1078644306 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 13 | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1556148976 |e 2963325754 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"bibl":"article-journal","media":"Online-Ressource"},"title":[{"title":"Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer","title_sort":"Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer"}],"name":{"displayForm":["Michael Thomas, Jürgen Fischer, Stefan Andreas, Cornelius Kortsik, Christian Grah, Monika Serke, Michael von Eiff, Christian Witt, Jens Kollmeier, Ernst Müller, Michael Schenk, Michael Schröder, Matthias Villalobos, Niels Reinmuth, Roland Penzel, Philipp Schnabel, Thomas Acker, Alexander Reuss, Martin Wolf"]},"origin":[{"dateIssuedKey":"2015","dateIssuedDisp":"July 2015"}],"id":{"eki":["1556148976"],"doi":["10.1183/09031936.00229014"]},"person":[{"display":"Thomas, Michael","role":"aut","family":"Thomas","given":"Michael"},{"family":"Villalobos Bollen","role":"aut","display":"Villalobos Bollen, Matthias Americo","given":"Matthias Americo"},{"role":"aut","display":"Reinmuth, Niels","family":"Reinmuth","given":"Niels"},{"given":"Roland","display":"Penzel, Roland","role":"aut","family":"Penzel"},{"given":"Philipp Albert","role":"aut","display":"Schnabel, Philipp Albert","family":"Schnabel"}],"note":["Gesehen am 31.03.2017"],"language":["eng"],"physDesc":[{"extent":"11 S."}],"recId":"1556148976","relHost":[{"note":["Gesehen am 25.04.2025","Fortsetzung der Druck-Ausgabe"],"corporate":[{"display":"European Respiratory Society","role":"isb"}],"recId":"306646803","physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"official journal of the European Society for Clinical Respiratory Physiology : ERJ"},{"title":"ERJ"}],"language":["eng"],"pubHistory":["1.1988 -"],"name":{"displayForm":["European Respiratory Society"]},"title":[{"subtitle":"flagship scientific journal of ERS","title_sort":"European respiratory journal","title":"The European respiratory journal"}],"disp":"Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancerThe European respiratory journal","origin":[{"publisher":"ERS ; Munksgaard","publisherPlace":"Lausanne ; Copenhagen","dateIssuedKey":"1988","dateIssuedDisp":"1988-"}],"part":{"pages":"219-229","text":"46(2015), 1, Seite 219-229","year":"2015","volume":"46","extent":"11","issue":"1"},"id":{"eki":["306646803"],"issn":["1399-3003"],"zdb":["1499101-9"]}}]} | ||
| SRT | |a THOMASMICHERLOTINIBA2015 | ||